FIBROBLAST GROWTH FACTOR 23 AS EARLY MARKER OF MINERAL AND BONE DISORDER IN PATIENTS WITH CHRONIC KIDNEY DISEASE

M. I. Chaikovska; L. P. Martynyuk

doi:10.31450/ukrjnd.1(57).2018.04

M. I. Chaikovska I. Horbachevsky Ternopil state medical university
L. P. Martynyuk I. Horbachevsky Ternopil state medical university

DOI: https://doi.org/10.31450/ukrjnd.1(57).2018.04

Keywords: chronic kidney disease, chronic renal failure, mineral bone disorders, fibroblast growth factor 23, parathyroid hormone, calcium, phosphorus

Abstract

The aim: to study the state of regulation of mineral metabolism in CKD by evaluating the serum concentration of c-terminal FGF-23, PTH, Ca, P, and to investigate the relationship between FGF-23 and PTH in CKD.

Materials and methods. The study involved 106 people with CKD, 47women (44%) and 59men (56%) aged (49.6 ± 13.9) years. The C-terminal FGF-23 fragment was determined using a set of reagents for the enzyme immunoassay «Biomedica». The glomerular filtration rate (GFR) was calculated using the CKD EPI formula (KDIGO 2012).

Results. A progressive increase in PTH levels was observed in parallel with the development of renal insufficiency in patients with CKD. Beginning with the CKD stage III, a significant increase above the norm (p <0.05) in the level of PTH ((85.79 ± 29.3) pg / ml) was observed. A progressive increase in the serum concentration of the c-terminal fragment of FGF-23 in patients with CKD was observed along with the GFR decrease. Statistically significant (p <0.05) increase in the concentration of FGF-23 was observed in CKD stage II ((1.29 ± 0.08) pmol / L) compared with CKD I ((0.76 ± 0.07) pmol / L). A strong negative association was found between FGF-23 and GFR (r = -0.87, p <0.05) in CKD. The existence of a strong direct association (r = 0.84, p <0.05) between the level of PTH and FGF-23 in CKD was established.

Conclusions. Growth of the level of FGF-23 outstrips the increase in PTH in the time interval by 1 stage of CKD. C-terminal FGF-23 can be used as an early marker of the development of mineral disturbances in patients with CKD.

Downloads

Download data is not yet available.

References

Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure / Isakova T, Houston J, Santacruz L, et al. // Pediatr Nephrol (Berlin, Germany). – 2013. – Vol. 28. – P. 2035–2042.

A systematic analysis of worldwide population–based data on the global burden of chronic kidney disease in 2010. K. T. Mills, Y. Xu, W. Zhang [et al.] // Kidney Int. – 2015. – Vol. 88. – P. 950–957.

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis / Gutierrez O. M., Mannstadt M., Isakova T., [et al.] // N Engl J Med. – 2008. – Vol. 359. – P. 584–592.

FGF23 induces left ventricular hypertrophy. C. Faul, A. P. Amaral, B. Oskouei [et al.] // The Journal of Clinical Investigation. – November 2011. – Vol. 121. – Number 11. – P. 4393–4408.

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 / R. Lozano, M. Naghavi, K. Foreman [et al.] // Lancet. – 2012. – Vol. 380. – P. 2095–2128.

Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta–Analysis [Electronic resource]/ N. R. Hill, S. T. Fatoba , J. L. Oke [et al.] // PLoS One. – 2.016. – Vol. 11(7). – Mode of access: https://doi.org/10.1371/journal.pone.0158765

The contribution of chronic kidney disease to the global burden of major noncommunicable diseases / W. G. Couser, G. Remuzzi, S. Mendis, M. Tonelli // Kidney Int. – 2011. – Vol. 80 (12). – P. 1258–1270.

Wolf M. Update on Fibroblast Growth Factor 23 in Chronic Kidney Disease // Kidney Int. – 2012. – Vol. 82(7). – P. 737–747.

Wyatt C. M. Fibroblast growth factor receptor 4: the missing link between chronic kidney disease and FGF23–induced left ventricular hypertrophy/ C. M. Wyatt, T. B. Drueke//Kidney Int. – January 2016. – Volume 89. – Issue 1. – P. 7–9.